The most common grade 3 or higher TRAE in both groups was neutropenia, which was reversible by symptomatic treatment (such as with granulocyte-colony stimulating factor), and its incidence rate was higher with IP/IC plus camrelizumab than with EP/EC plus PD-L1 inhibitor. Here, CD274 is linked to Decreased total neutrophil count.